Transcript for Supreme Court reviews opioid settlement
DERRICKE DENNIS: It's a potential watershed moment in the opioid epidemic. Today, the Supreme Court will review a $6 billion bankruptcy settlement between Purdue Pharma, the maker of OxyContin, and the victims and communities ravaged by the opioid crisis. At issue, the deal gives Purdue Pharma's owners, the Sackler family, immunity, protecting them from lawsuits.
- The victims fought for this plan because they want to help people who have lost loved ones, who have been affected by the opioid crisis, to recover money.
DERRICKE DENNIS: Attorney Edward Neiger helped negotiate the settlement and wants it upheld, but the Justice Department is opposed, arguing there must be unanimous consent among all the claimants to give the Sackler family, which made billions off OxyContin, immunity.
- The Sacklers may be bad people, but they're not stupid people. And they will not give any money to abate the opioid crisis or to victims to help rebuild their lives, unless they get those releases. If they really want to make a lesson of what the Sacklers did, they can and should criminally prosecute the Sacklers.
DERRICKE DENNIS: Ellen Isaacs lost her son, Ryan, to an overdose after he was prescribed OxyContin at 16-years-old, Her attorney, Michael Quinn, is seeking a jury trial to keep the Sackler family on the hook.
- In a way, this case is about deterrence. It's about holding corporate leaders and owners accountable for their business decisions.
- If approved, the bankruptcy settlement would pay $6 billion to individual families, state health programs, and Native American tribes over the next 18 years. But if the deal is blocked, legal experts say it could set a precedent for how corporate bankruptcy cases are settled.
This transcript has been automatically generated and may not be 100% accurate.